GLP‑1 drugs may fight addiction across every major substance, according to a study of 600,000 people / Medical Express

medicalxpress - A patient of mine, a veteran who had tried to quit smoking for over a decade, told me that after he started a GLP-1 drug for his diabetes, he lost interest in cigarettes. He didn't use a patch. He didn't set a quit date. He simply lost interest. It happen…

4 days / oncodaily

GLP‑1 drugs may fight addiction across every major substance, according to a study of 600,000 people

6 days / medicalxpress

GLP-1 drugs tied to lower addiction risk: Study

6 days / beckershospitalreview / Ella Jeffries

GLP‑1 drugs like Ozempic may lower the risk of addiction: New study

6 days / medicalxpress

Friday, March 6, 2026, 12:23 pm / permalink 20276 / 8 stories in 4 days

AI blood test finds silent liver disease years before symptoms / Science Daily Cancer

sciencedaily - Researchers created an AI-driven liquid biopsy that scans patterns in fragments of DNA circulating in the blood. The system detected early liver fibrosis and cirrhosis—conditions that often go unnoticed until serious damage occurs. By analyzing genome-wid…

#healthcare #publichealth #biotech #digitalhealth #medicaldevices #healthcarefinance

Ali Choukair Presents a 360° Approach to Metabolic Liver Disease – Emirates Digestive Diseases Week

4 days / oncodaily

ImmunoXXL Phase 2 Study: Liver Transplantation After Atezolizumab–Bevacizumab Downstaging in Advanced HCC

4 days / oncodaily

AI blood test finds silent liver disease years before symptoms

5 days / sciencedaily

AI-based liquid biopsy may detect liver fibrosis, cirrhosis and chronic disease signals

6 days / medicalxpress

Cell-free DNA fragmentomes for noninvasive detection of liver cirrhosis and other diseases

7 days / science / Akshaya V. Annapragada, Zachariah H. Foda, Hope Orjuela, Carter Norton, Shashikant Koul, Noushin Nik

Friday, March 6, 2026, 1:22 am / permalink 20251 / 5 stories in 5 days

Groundbreaking new drug shows promise for treating children with a devastating form of epilepsy / LiveScience

livescience - An experimental treatment reduces seizures and other symptoms in children with a type of epilepsy called Dravet syndrome.

#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #fda #infanthealth

Groundbreaking new drug shows promise for treating children with a devastating form of epilepsy

5 days / livescience

Drug breakthrough for children with severe form of epilepsy

6 days / bbc

First gene regulation clinical trials for epilepsy show promising results

6 days / medicalxpress

Life-changing drug identified for children with rare epilepsy

6 days / medicalxpress

Thursday, March 5, 2026, 4:23 pm / permalink 20233 / 4 stories in 5 days

Amazon launches Amazon Connect Health / Beckers

Naomi Diaz / beckershospitalreview - Amazon Web Services has launched Amazon Connect Health, an artificial intelligence tool designed to automate administrative tasks for health systems and improve patient access to care. Here are six things to know about Amazon Connect Health: Amazon Connec…

#healthcare #digitalhealth #hospitaloperations #healthcarefinance

Richard Dirven Calls for Responsible Integration of AI in Precision Oncology Care

4 days / oncodaily

CVS, Humana & More Are Turning to Google’s AI Models

4 days / medcitynews / Katie Adams

Highmark Health generates $28M in value with Google AI

4 days / beckershospitalreview / Giles Bruce

Privacy Expectations in Consumer AI Tools: How Patient Use of ChatGPT Health and Claude Differs From HIPAA-Regulated Care

5 days / medcitynews / Nirmal Vemanna

How to use AI tools to support our wellbeing in safe and simple ways

5 days / bbc

Future of Health Tech: From Structured Data to Scalable AI [Video]

5 days / medcitynews / wlim

Salesforce partners with HealthEx, Verily and Viz.ai to build out healthcare AI agents

5 days / fiercehealthcare

Optum expands Microsoft collaboration to add AI to claims platform

5 days / beckershospitalreview / Naomi Diaz

4 health system leaders join initiative to improve patient safety with AI

5 days / beckershospitalreview / Giles Bruce

AI Startups Are Tying Fees to Completed Tasks. Will Hospitals Buy In?

5 days / medcitynews / Katie Adams

Microsoft unveils new Dragon Copilot AI capabilities for clinicians

5 days / beckershospitalreview / Naomi Diaz

Optum teams with Microsoft to expand AI-powered claims platform

5 days / fiercehealthcare

Waystar expanding Google Cloud collaboration

5 days / beckershospitalreview / Andrew Cass

The algorithm will see you now? Patients say not without a doctor nearby

5 days / medicalxpress

Amazon launches Amazon Connect Health

6 days / beckershospitalreview / Naomi Diaz

Amazon launches suite of healthcare AI agents

6 days / healthcaredive / Emily Olsen

When Artificial Intelligence Starts Rewriting Reality

6 days / thehealthcareblog / matthew holt

AWS offers agentic AI solution to tackle scheduling, ambient note-taking and medical coding

6 days / fiercehealthcare

Thursday, March 5, 2026, 11:23 am / permalink 20205 / 18 stories in 5 days

Adding Hormone Therapy to PORT Might Not Benefit Patients with Recurrent Prostate Cancer and PSA of 0.5 ng/mL or Less / ESMO

esmo - Findings from the POSEIDON meta-analysis of the MARCAP consortium

#healthcare #pharmaceuticals #publichealth #oncology

Adding Hormone Therapy to PORT Might Not Benefit Patients with Recurrent Prostate Cancer and PSA of 0.5 ng/mL or Less

6 days / esmo

Majid Al Othman: POSEIDON Meta-Analysis Results in Post-Prostatectomy Salvage RT

9 days / oncodaily

Sault skiiers bring home medals from youth championships

11 days / sootoday

Thursday, March 5, 2026, 3:23 am / permalink 20175 / 3 stories in 6 days

Novo Nordisk inks $2.1B oral obesity drug deal / Beckers

Ella Jeffries / beckershospitalreview - Novo Nordisk has partnered with Vivtex Corp. to develop next-generation oral biologic medicines for obesity, diabetes and related conditions. Under the agreement, Vivtex will license its proprietary oral drug-delivery technologies to Novo Nordisk and is e…

#obesity #healthcare #pharmaceuticals #novonordisk #weightloss #biotech #drugdevelopment #healthcarefinance

Pfizer gets obesity drug approval in China shortly after buying local rights

5 days / endpoints / Elizabeth Cairns

Trial suggests GLP-1 combo therapy cuts fat while preserving muscle in obesity

5 days / medicalxpress

Roche partner Zealand posts Phase 2 data for amylin obesity drug

5 days / endpoints / Kyle LaHucik

Novo Nordisk details Irish expansion; EuroAPI’s challenges continue

6 days / endpoints / Anna Brown

What to know about how GLP-1 medications might fight addiction

6 days / medicalxpress

Twenty percent of eligible youth prescribed GLP-1 receptor agonists

6 days / medicalxpress

GLP-1 medications get at the heart of addiction, study finds

6 days / medicalxpress

Quitting GLP-1 drugs triggers rapid regain, but 25% of weight loss may last

6 days / medicalxpress

Eli Lilly launches its direct-to-employer platform for obesity drugs

6 days / fiercehealthcare

Most Patients Keep Weight Off With Fewer GLP-1 Shots, Study Finds

6 days / nytimes / Roni Caryn Rabin

AHA urges HHS to block Novo Nordisk’s 340B data demand

6 days / beckershospitalreview / Paige Twenter

FDA sends Novo Nordisk 2nd warning over GLP-1 ads

6 days / beckershospitalreview / Erica Cerutti

How gut bacteria and diet can reprogram fat to burn more energy

7 days / medicalxpress

No more weekly injections? How lettuce cells could deliver GLP-1 pills

7 days / medicalxpress

GLP-1 weight-loss drugs comparably effective across age, race and starting weight

7 days / medicalxpress

FDA ramps up crackdown on GLP-1 drug compounding with fresh batch of 30 warning letters

7 days / fiercehealthcare

FDA warns 30 telehealth firms over compounded GLP-1 claims

7 days / beckershospitalreview / Ella Jeffries

Hims partner Strive Pharmacy will reintroduce GLP-1 pill pulled from market

8 days / endpoints / Shelby Livingston

Novo Nordisk inks $2.1B oral obesity drug deal

9 days / beckershospitalreview / Ella Jeffries

Novo Nordisk Commits Up to $2B to Drug Delivery Startup Vivtex for R&D of Oral Metabolic Meds

13 days / medcitynews / Frank Vinluan

Novo Nordisk teams with Langer-founded biotech for oral obesity drugs

14 days / endpoints / Kyle LaHucik

Tuesday, March 3, 2026, 1:22 am / permalink 20039 / 21 stories in 8 days

RFK Jr. names 2 new members to CDC vaccine panel / Beckers

Erica Cerutti / beckershospitalreview - HHS Secretary Robert F. Kennedy Jr. appointed two new members to the CDC’s vaccine advisory committee Feb. 27, ahead of a rescheduled meeting in mid-March where members are expected to review COVID-19 vaccine recommendations. Mr. Kennedy said Sean Downing…

#healthcare #publichealth #governmentpolicy #cdc #vaccinesafety #infectiousdisease

HHS strikes deal with 53 medical schools to expand nutrition training

5 days / beckershospitalreview / Erica Cerutti

Dozens of medical schools meet RFK Jr.'s call for greater nutrition education

5 days / fiercehealthcare

Minnesota sues feds over nearly $244M in frozen Medicaid funds

6 days / beckershospitalreview / Elizabeth Casolo

In South Carolina Measles Outbreak, Vaccine Skepticism Led to Largest Outbreak Since 2000

8 days / nytimes / Anemona Hartocollis and Kaoly Gutierrez

U.S. tops 1,100 measles cases this year as outbreaks grow

8 days / medicalxpress

Two more members added to ACIP ahead of March meeting

8 days / endpoints / Max Bayer

Kennedy adds 2 new members to CDC’s vaccine panel ahead of delayed meeting

8 days / fiercehealthcare

RFK Jr. names 2 new members to CDC vaccine panel

9 days / beckershospitalreview / Erica Cerutti

Monday, March 2, 2026, 3:24 pm / permalink 20024 / 8 stories in 8 days

Parents of gravely ill child refused respite care / BBC

bbc - Birmingham Children's Trust refused respite help and suggested training grandparents to help.

#healthcare #publichealth #governmentpolicy #behavioralhealth

'Moment of reckoning' needed in social care, says Louise Casey

5 days / bbc

Trying to get social care can be 'horrendous', Baroness Casey tells BBC

6 days / bbc

Families Defend Disability Services Amid Medicaid Cuts

9 days / kffhealthnews / Bram Sable-Smith

E-biking boosts health, physical activity levels, study finds

12 days / medicalxpress

Parents of gravely ill child refused respite care

12 days / bbc

Monday, March 2, 2026, 2:22 am / permalink 19974 / 5 stories in 9 days

Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours / ESMO

esmo - Findings from the PYNNACLE study

#healthcare #pharmaceuticals #biotech #drugdevelopment #oncology

Rezatapopt Shows Early Activity in TP53 Y220C–Mutated Solid Tumors

7 days / oncodaily

Targeting the untargetable cancer—rezatapopt, an oral p53 reactivator

9 days / medicalxpress

Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours

9 days / esmo

Jayastu Senapati: Trial of Rezatapopt in TP53-Y220C Mutated MDS/AML

10 days / oncodaily

Rashid Lui: First-in-Class Oral Selective p53 Reactivator Looks Promising

11 days / oncodaily

Xin Lu on Targeting Mutant p53 in Solid Tumors with Rezatapopt – NEJM Group

11 days / oncodaily

Florent Peyraud: Restoring Function to a Variant of p53 in Solid Tumors

12 days / oncodaily

Aydah AlAwadhi: Targeting the “Undruggable” p53 – A Long Awaited Proof of Principle

12 days / oncodaily

Monday, March 2, 2026, 2:22 am / permalink 19973 / 8 stories in 9 days

Novartis closes Avidity deal as rare heart disease spinout launches / Endpoints

Lei Lei Wu / endpoints - Atrium Therapeutics launched Friday morning as Novartis closed the $12 billion deal to buy Avidity Biosciences and its RNA muscle therapies. The spinout will take on Avidity’s early-stage programs for genetic cardiomyopathies — heart muscle diseases ...

#healthcare #pharmaceuticals #biotech #mergersandacquisitions #corporatetakeover #drugdevelopment #healthcarefinance

Atrium Therapeutics Launches With $270M for RNA Therapies Addressing Rare Cardio Conditions

10 days / medcitynews / Frank Vinluan

Novartis closes Avidity deal as rare heart disease spinout launches

12 days / endpoints / Lei Lei Wu

Monday, March 2, 2026, 12:23 am / permalink 19968 / 2 stories in 9 days

Health Gorilla Calls Epic Lawsuit ‘Attack on Interoperability’ in Motion to Dismiss / MedCity

Katie Adams / medcitynews - Health data company Health Gorilla filed a motion to dismiss a lawsuit from Epic and several healthcare providers alleging inappropriate access to nearly 300,000 patient records. The case highlights ongoing questions about governance and standards for nat…

#healthcare #governmentpolicy #digitalhealth #hospitaloperations

Researchers call for governing health data as a public utility to unlock real-world evidence and protect patients

5 days / medicalxpress

HHS gets serious on information blocking enforcement

6 days / healthcaredive / Sydney Halleman

DoseSpot, Arrive Health merge to combine prescribing tools with pharmacy, medical benefit data

9 days / fiercehealthcare

Health Gorilla Calls Epic Lawsuit ‘Attack on Interoperability’ in Motion to Dismiss

9 days / medcitynews / Katie Adams

Health Gorilla urges court to toss lawsuit filed by Epic, health systems

12 days / fiercehealthcare

Health Gorilla files motion to dismiss lawsuit filed by Epic, health systems

12 days / beckershospitalreview / Naomi Diaz

Sunday, March 1, 2026, 6:23 pm / permalink 19963 / 6 stories in 9 days

After 4-Week Strike, Kaiser Permanente Workers Score Tentative Win on Staffing & Pay / MedCity

Katie Adams / medcitynews - About 31,000 Kaiser Permanente workers ended a four-week strike after reaching a tentative agreement that includes measures to address chronic understaffing and wage increases. The full contract has not yet been ratified.The post After 4-Week Strike, Kais…

#healthcare #publichealth #hospitaloperations #healthcarefinance

The Kaiser Settlement Should End the Guesswork in Medicare Advantage Oversight

6 days / medcitynews / David Lareau

2,400 Kaiser mental health workers to hold 1-day strike

6 days / beckershospitalreview / Kelly Gooch

Your Anesthesia Subsidy: Key Questions Every Hospital C-Suite Must Answer

9 days / beckershospitalreview / Vedant Bhosale

Four Proven Approaches to Stabilizing Clinical Operations

9 days / beckershospitalreview / Vedant Bhosale

Clinician Engagement: The Operating Lever Behind Margin and Throughput

9 days / beckershospitalreview / Vedant Bhosale

Work environment, moral resilience help nurses prevent moral injury

9 days / medicalxpress

After 4-Week Strike, Kaiser Permanente Workers Score Tentative Win on Staffing & Pay

13 days / medcitynews / Katie Adams

31,000 Kaiser workers end strike; mental health clinicians back walkout: 6 notes

15 days / beckershospitalreview / Kelly Gooch

Saturday, February 28, 2026, 12:22 pm / permalink 19945 / 8 stories in 10 days

Merck Splits Oncology Business Unit as Keytruda Patent Expiry Nears / OncoDaily

oncodaily - On February 23, 2026, Merck announced a reorganization of its Human Health structure into two business units: an Oncology Business Unit and a Specialty, Pharma & Infectious Diseases Business Unit. […]

#healthcare #pharmaceuticals #biotech #drugdevelopment #oncology #healthcarefinance

Merck KGaA drops two cancer trials on assets from SpringWorks deal

6 days / endpoints / Reynald Castaneda

No OS Improvement with CDK4/6 Inhibitors Used in First- Compared with Second-Line Treatment in Patients with HR-positive, HER2-negative ABC

8 days / esmo

Cancer Research UK partners with the Royal College of Surgeons of England to help people with rectal cancer avoid unnecessary surgery

8 days / cancerresearchuk / Krishna Sharma

A domain-adaptive deep contrastive network for magnetic resonance imaging-driven bladder cancer classification

8 days / nature

Multicenter ex vivo evaluation of an α-mannosidase–targeted fluorescent probe for intraoperative margin assessment in breast cancer

8 days / nature

Neoadjuvant pembrolizumab plus chemotherapy in older patients with early-stage triple-negative breast cancer: real-world insights from neo-real/GBECAM-0123

8 days / nature

Merck looks to expand Welireg label following combo readouts with Keytruda, Lenvima

11 days / endpoints / Nicole DeFeudis

Merck Splits Oncology Business Unit as Keytruda Patent Expiry Nears

12 days / oncodaily

Merck reorganizes; Blackstone to fund trials for J&J drug

16 days / endpoints / ENDPOINTS

Saturday, February 28, 2026, 3:22 am / permalink 19937 / 9 stories in 11 days

Teladoc Health reports slower growth, offers cautious 2026 outlook as it shifts telehealth model / Fierce

fiercehealthcare - Teladoc Health reported better-than-expected fourth quarter financial results with both revenue and earnings exceeding analysts' expectations, driving a 15% jump in the company's stock Thursday.

#healthcare #governmentpolicy #digitalhealth #healthcarefinance

Why Telehealth Skills Belong at the Core of Clinical Education

10 days / beckershospitalreview / Nikhil Gaikwad

Teladoc Health reports slower growth, offers cautious 2026 outlook as it shifts telehealth model

12 days / fiercehealthcare

Teladoc projects lower integrated care membership amid ACA subsidy lapse

12 days / healthcaredive / Emily Olsen

Saturday, February 28, 2026, 3:22 am / permalink 19936 / 3 stories in 11 days

CFO Mark Kaye to take the helm at Carelon in leadership shake-up at Elevance Health / Fierce

fiercehealthcare - Elevance Health Chief Financial Officer Mark Kaye will grow his list of duties to include oversight of Carelon, the company announced Thursday.

#healthcare #digitalhealth #behavioralhealth #healthcarefinance

CMS threatens Elevance with Medicare Advantage sanctions

8 days / healthcaredive / Rebecca Pifer Parduhn

CMS set to suspend enrollment in Elevance Health's Medicare Advantage plans

8 days / fiercehealthcare

CMS to suspend enrollment into Elevance’s Medicare Advantage plans

9 days / beckershospitalreview / Elizabeth Casolo

How Leading Health Systems Are Mastering the Next Capacity Surge

9 days / beckershospitalreview / Vedant Bhosale

Elevance shuffles C-suite as top Carelon exec departs

12 days / healthcaredive / Rebecca Pifer Parduhn

CFO Mark Kaye to take the helm at Carelon in leadership shake-up at Elevance Health

12 days / fiercehealthcare

Saturday, February 28, 2026, 2:21 am / permalink 19934 / 6 stories in 11 days

First-ever in-utero stem cell therapy for fetal spina bifida repair shows safe results / Medical Express

medicalxpress - A Phase I clinical trial published in The Lancet has shown that combining stem cell therapy with standard fetal surgery before birth is a safe and promising approach to treat myelomeningocele, a severe form of spina bifida. This is the first time live ste…

#healthcare #biotech #drugdevelopment #infanthealth

Stem cell patch reverses brain damage in fetuses with spina bifida

12 days / newscientist

First-ever in-utero stem cell therapy for fetal spina bifida repair shows safe results

12 days / medicalxpress

Saturday, February 28, 2026, 1:22 am / permalink 19931 / 2 stories in 11 days

Microplastics discovered in prostate tumors / Medical Express

medicalxpress - Small fragments of plastic were found in 9 out of 10 patients with prostate cancer, and in higher levels inside tumors than in nearby noncancerous tissue, a new study finds. The small, single-center study was led by researchers at NYU Langone Health, its …

#healthcare #publichealth #oncology

How worried should you be about microplastics?

7 days / newscientist

María Natalia Gandur Quiroga: Structural Shifts in How We Think About Prostate Cancer

10 days / oncodaily

Microplastics found in 90% of prostate cancer tumors, study reveals

14 days / sciencedaily

Microplastics discovered in prostate tumors

15 days / medicalxpress

Saturday, February 28, 2026, 12:23 am / permalink 19928 / 4 stories in 11 days

Boehringer wins accelerated approval for first-line use of lung cancer drug / Endpoints

Lei Lei Wu / endpoints - The FDA greenlit an expanded label for Boehringer Ingelheim’s lung cancer drug Hernexeos, marking the first use of the Commissioner's National Priority Voucher for a new indication. Boehringer won an accelerated

#healthcare #pharmaceuticals #publichealth #governmentpolicy #biotech #drugdevelopment #fda #oncology

What to know about lung cancer

6 days / medicalxpress

Lurbinectedin in Oncology: Mechanism, Clinical Data, Evolving Role, and Future Directions

9 days / oncodaily

Patrick Soon-Shiong: Anktiva Plus Keytruda Shows Potential to Prolong Survival in Patients with Lung Cancer

10 days / oncodaily

Aakash Desai HER2-Mutant NSCLC: Navigating the TKI vs ADC Debate

10 days / oncodaily

Stephen V Liu: Intracranial Efficacy of Trastuzumab Deruxtecan in HER2-Mutant NSCLC

10 days / oncodaily

FDA Approves Zongertinib for HER2-Mutated NSCLC – Oncology Brothers

10 days / oncodaily

Zongertinib Receives FDA Accelerated Approval in HER2-Mutant NSCLC

11 days / oncodaily

FDA Voucher Leads to Speedy Approval of Boehringer Drug for First-Line Use in Lung Cancer

12 days / medcitynews / Frank Vinluan

Boehringer wins accelerated approval for first-line use of lung cancer drug

12 days / endpoints / Lei Lei Wu

Saturday, February 28, 2026, 12:23 am / permalink 19927 / 9 stories in 11 days

Novartis to build $23B radioligand therapy site / Beckers

Ella Jeffries / beckershospitalreview - Novartis will construct a 46,000-square-foot radioligand therapy manufacturing site in Denton, Texas, as part of its $23 billion U.S. investment. The facility will be Novartis’ fifth radioligand therapy site in the U.S. and its first in Texas, according t…

#healthcare #pharmaceuticals #biotech #drugdevelopment #oncology #healthcarefinance

Oklahoma pharmacy school to expand radiopharmaceutical access with new facility

6 days / beckershospitalreview / Ella Jeffries

Novartis to build $23B radioligand therapy site

12 days / beckershospitalreview / Ella Jeffries

Novartis to build another radioligand factory; Germany steps up probe into Gerresheimer

13 days / endpoints / Anna Brown

Saturday, February 28, 2026, 12:23 am / permalink 19926 / 3 stories in 11 days

Patient dies in MacroGenics' cancer study, FDA puts trial on hold / Endpoints

Max Gelman / endpoints - The FDA has placed a partial clinical hold on MacroGenics’ Phase 2 study in gynecologic cancers after one patient died and three others experienced life-threatening side effects, the company disclosed Tuesday. The patient who died ...

#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #fda #oncology

Kyowa Kirin ends OX40 trials after Amgen balked, safety concern

7 days / endpoints / Kyle LaHucik

FDA partially pauses cancer drug trial after patient death

13 days / beckershospitalreview / Paige Twenter

Patient dies in MacroGenics' cancer study, FDA puts trial on hold

15 days / endpoints / Max Gelman

Saturday, February 28, 2026, 12:23 am / permalink 19925 / 3 stories in 11 days

Tag Directory / HEALTHCARE showing 21–40 of 261

GLP‑1 drugs may fight addiction across every major substance, according to a study of 600,000 people / Medical Express

AI blood test finds silent liver disease years before symptoms / Science Daily Cancer

Groundbreaking new drug shows promise for treating children with a devastating form of epilepsy / LiveScience

Amazon launches Amazon Connect Health / Beckers

Adding Hormone Therapy to PORT Might Not Benefit Patients with Recurrent Prostate Cancer and PSA of 0.5 ng/mL or Less / ESMO

Novo Nordisk inks $2.1B oral obesity drug deal / Beckers

RFK Jr. names 2 new members to CDC vaccine panel / Beckers

Parents of gravely ill child refused respite care / BBC

Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours / ESMO

Novartis closes Avidity deal as rare heart disease spinout launches / Endpoints

Health Gorilla Calls Epic Lawsuit ‘Attack on Interoperability’ in Motion to Dismiss / MedCity

After 4-Week Strike, Kaiser Permanente Workers Score Tentative Win on Staffing & Pay / MedCity

Merck Splits Oncology Business Unit as Keytruda Patent Expiry Nears / OncoDaily

Teladoc Health reports slower growth, offers cautious 2026 outlook as it shifts telehealth model / Fierce

CFO Mark Kaye to take the helm at Carelon in leadership shake-up at Elevance Health / Fierce

First-ever in-utero stem cell therapy for fetal spina bifida repair shows safe results / Medical Express

Microplastics discovered in prostate tumors / Medical Express

Boehringer wins accelerated approval for first-line use of lung cancer drug / Endpoints

Novartis to build $23B radioligand therapy site / Beckers

Patient dies in MacroGenics' cancer study, FDA puts trial on hold / Endpoints

HEALTHCARE Heatmap

More Top Stories...

FDA refuses to review Moderna mRNA flu vaccine application

FDA CRL halts AstraZeneca’s Saphnelo prefilled pen approval

CMS proposes sweeping changes to ACA marketplace plan rules

Tenet forecasts major ACA exchange enrollment drop and financial hit

City of Hope promotes Nisha Morris to senior marketing chief